Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience and DM Complications and Metabolic Diseases. With over 17,000 global employees, Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia

Astellas Provides Update On Izervay (Avacincaptad  Pegol Intravitreal Solution) Supplemental New Drug  Application

Supplementary Documents (Q2 Ytd/Fy2024)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Astellas Pharma (4503 JP)

Astellas Provides Update On Izervay (Avacincaptad Pegol Intravitreal Solution) Supplemental New Drug Application

Supplementary Documents (Q2 Ytd/Fy2024)

Presentation Material For Information Meeting (Q2 Ytd/Fy2024)

Financial Results (Q2 Ytd/Fy2024)

Notice Regarding Foreign Exchange Loss

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)